The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Mon., Jan. 26, 3:22 AM

Slide #18. Keryx Biopharmaceuticals, Inc. Secondary Offering

Company: Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX)
Date announced: 1/20/2015
Shares Offered: 9,166,667.00
Date of Pricing: 1/21/2015
Price Per Share: $12.00
Secondary Offering Details: Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that it has commenced a $100 million underwritten public offering of shares of its common stock. In connection with this offering, Keryx expects to grant to the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. J.P. Morgan is acting as the sole book-running manager in the offering. Keryx intends to use the net proceeds from the sale of its common stock to fund the ongoing commercialization and development of Auryxia in the US, pre-commercial activities in Europe, to potentially in-license, acquire and develop additional drug candidates, and other general corporate purposes. - updated 1/22 - Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced the pricing of an underwritten public offering of common stock consisting of 9,166,667 shares at $12.00 per share, for gross proceeds of $110 million. In connection with this offering, Keryx granted to the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. Keryx intends to use the net proceeds from the sale of its common stock to fund the ongoing commercialization and development of Auryxia (ferric citrate) in the US, pre-commercial activities in Europe, to potentially in-license, acquire and develop additional drug candidates, and other general corporate purposes.

Keryx Biopharmaceuticals is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease. Co. is developing Zerenex™, an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. Co. has completed a clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney disease (CKD) on dialysis; and a study of Zerenex for the management of elevated serum phosphorus levels and iron deficiency anemia in subjects with Stage 3 to 5 non-dialysis dependent CKD.
Open the KERX Page at The Online Investor »

Company Name:  Keryx Biopharmaceuticals Inc.
Website:  www.keryx.com
Sector:  Biotechnology
Number of ETFs Holding KERX:  17
Total Market Value Held by ETFs:  $60.39M
Total Market Capitalization:  $1.18B
% of Market Cap. Held by ETFs:  5.10%
 

Open the KERX Page at The Online Investor (in a new window) »

January 26, 2015    3:22 AM Eastern
Quotes delayed 20 minutes



Strong Buy (3.60 out of 4)
75th percentile
(ranked higher than approx. 75% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.